Thelansis

Facioscapulohumeral Muscular Dystrophy (FSHD) Market Outlook Thelansis’s “Facioscapulohumeral Muscular Dystrophy (FSHD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Facioscapulohumeral Muscular Dystrophy (FSHD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Whic...

Facioscapulohumeral Muscular Dystrophy (FSHD) Market Outlook Thelansis’s “Facioscapulohumeral Muscular Dystrophy (FSHD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Facioscapulohumeral Muscular Dystrophy (FSHD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Facioscapulohumeral Muscular Dystrophy (FSHD) Overview Facioscapulohumeral muscular dystrophy (FSHD) stands out as a genetic muscle disorder with a primary impact on facial, shoulder, and upper arm muscles. This condition is categorized into type 1 (FSHD1) and type 2 (FSHD2), presenting identical signs and symptoms but differing in their genetic origins. Initially, FSHD...

 Facioscapulohumeral muscular dystrophy (FSHD) stands out as a genetic muscle disorder with a primary impact on facial, shoulder, and upper arm muscles. This condition is categorized into type 1 (FSHD1) and type 2 (FSHD2), presenting identical signs and symptoms but differing in their genetic origins. Initially, FSHD manifests as facial, shoulder girdle, and arm muscle weakness. Facial weakness may lead to restricted lip movements, causing challenges like whistling, using a straw, or puckering the lips. Notably, individuals with FSHD may acquire a distinctive "mask-like" facial appearance. Upper facial weakness can also result in an inability to close the eyes during sleep. FSHD1 is attributed explicitly to abnormal expression of the DUX4 gene, found on chromosome 4 in the D4Z4 region. The DNA in this region usually undergoes hypermethylation and contains 11-100 repeated DNA segments. Notably, each pregnancy involving an affected parent carries a 50% risk of passing on the ab...